Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Dylan Hamilton"'
Autor:
Sarah Grace Young, Jossellyn Vieyra-Sanchez, Anna Salazar, Samuel Hudson, Dylan Hamilton, Daniela Wolter Ferreira Touma
Publikováno v:
2022 Wireless Power Week (WPW).
Autor:
Barry Caplan, Victor Liu, Mary Beth Clarke, Dylan Hamilton, Gary C. du Moulin, Bruce Babbitt, Joseph J. Goodwin
Publikováno v:
Biotechnology and Bioengineering. 43:700-705
An in vitro assay that measures the activation level of ex vivo activated (EVA) T cells currently being used in the adoptive immunotherapy of metastatic renal cell carcinoma has been developed. This assay is based on the ability of activated, but not
Autor:
Carla Charles, Brian Davies, Victor Liu, Letinh Ho, Jessica Stack, Yuan-Jin Shen, Gary C. du Moulin, Evelyn Conti, Judy Chew-Darke, Zorina Pitkin, Dylan Hamilton, Carolyn Cyr, Adrienne White
Publikováno v:
Biotechnology and bioengineering. 43(8)
Autolymphocyte therapy (ALT) is outpatient-based adoptive immunotherapy using ex vivo-activated memory T-cells. To support the safe and reproducible delivery of ALT at three cell processing facilities (Boston, MA; Atlanta, GA; Orange, CA) we created
Autor:
Jean Ko Stewart, Yuan-Jin Shen, Gary C. du Moulin, Carla Charles, Dylan Hamilton, Zorina Pitkin, Evelyn Conti
Publikováno v:
Cell Culture Engineering IV ISBN: 9789401041140
Somatic cell and gene therapy involve the application of biological technologies to an individual patient through the use of living cells which provide a therapeutic benefit (Aliski, 1991). Various forms of cellular and gene therapies are being devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ecb4a7e00fbbe4c99eba8aa9b178a48
https://doi.org/10.1007/978-94-011-0257-5_39
https://doi.org/10.1007/978-94-011-0257-5_39
Autor:
Michael E. Osband, Victor Liu, F. Miesowicz, G. Du Moulin, B. Davies, Dylan Hamilton, J. Chew-Darke, Zorina Pitkin, J. Stack
Publikováno v:
Cell Transplantation, Vol 3 (1994)
Publikováno v:
World Journal of Urology. 4:217-221
We report the results from a clinical trial of adoptive immunotherapy conducted in 20 patients with metastatic renal cell carcinoma, a form of cancer unresponsive to traditional modalities of treatment. This novel approach is based on our previously